VPG & Volition launch Nu.Q® Test in UK & Ireland



Exeter, UK, 6th November 2023 – Veterinary Pathology Group (VPG), a high quality leading diagnostic laboratory, and VolitionRx Limited (Volition), a multi-national epigenetics company, have joined forces to launch the Nu.Q® Test to veterinary practices in the UK and Ireland.

VPG is the first-to-market diagnostic laboratory in the UK and Ireland to offer the Nu.Q® Test, a groundbreaking tool for the early detection and monitoring of cancer in dogs.

Volition’s Nu.Q® Test is an accessible and affordable screening tool for dogs with increased risk of developing cancer, such as older dogs, certain breeds with higher cancer prevalence rates and those dogs with familial history.

Dr Tom Butera, Chief Executive Officer, Volition Veterinary Diagnostics Development LLP said “Working with VPG, we are thrilled to be rolling out the Nu.Q® Test to veterinary practices across the UK and Ireland, two renowned pet-loving nations. It is a non-invasive blood test that can easily integrate into preventive care plans. Veterinarians can run the test alongside routine blood work and imaging, to help provide earlier cancer detection, improve a dog’s quality of life and give a better chance of effective treatment.”

Fiona Gosling, Chief Executive Officer at VPG, said “Our collaboration with Volition highlights the commitment of both organisations to improving the quality of life for pets and supporting veterinary professionals in their mission to provide the best possible care.

“By integrating the revolutionary Nu.Q® Test into our diagnostic portfolio, we are expanding our wellness testing offering and empowering veterinarians with an accessible, cutting edge tool to detect cancer in its early stages, ultimately leading to better outcomes and improved patient care.

“Veterinary practices interested in offering the Nu.Q® Test to their clients can find out more here”.